This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, S.-C. Articles by Chou, C.-Y. Search for Related Content PubMed PubMed Citation Articles by Huang, S.-C. Articles by Chou, C.-Y.

Fas and Its Ligand, Caspases, and Bcl-2 Expression in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma

Department of Obstetrics and Gynecology (S.-C.H., K.-F.H., Y.-M.C., C.-Y.C.), Institute of Clinical Medicine (S.-C.H., M.-J.T., K.-F.H., C.-Y.C.), and Department of Physiology (M.-J.T.), College of Medicine, National Cheng Kung University, Tainan 704, Taiwan

Address all correspondence and requests for reprints to: Cheng-Yang Chou, M.D., Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 704, Taiwan. E-mail: chougyn{at}mail.ncku.edu.tw.

Abstract

GnRH agonist (GnRH-a) therapy is known to shrink uterine leiomyoma, although the molecular mechanisms responsible for this effect remain poorly understood. Conflicting results exist as to whether GnRH-a treatment increases apoptosis in leiomyoma cells. The aim of this study is to investigate the effects of GnRH-a on uterine leiomyomas by profiling the expression levels of apoptosis-related molecules such as Fas/Fas ligand (FasL), caspases 3, 6, 7, 8, 9, and 10, and Bcl-2 from specimens of 20 patients receiving Leuplin Depot (LA), a long-acting GnRH-a, of 3 doses before myomectomy, as well as 24 controls. We found that uterine leiomyomas had up-regulated expressions of FasL and caspase 3 as compared with their homologous normal myometrium control. Both leiomyomas and myometria from LA-treated patients, however, presented a significant decrease in the expressions of FasL and caspase 3 as compared with those from LA-naive control patients. In addition, it was at the posttranscription level that the tumorigenesis of leiomyoma modulated the expressions of FasL and caspase 3 higher, whereas LA suppressed them at gene transcription. Unlike the case of FasL and caspase 3 mentioned above, no significant difference was found between leiomyomas and homologous myometria in the expressions of Fas and caspases 6, 7, 8, 9, and 10. The LA effect made drug-treated leiomyomas produce less Fas and caspases 7, 9, and 10 as compared with nontreated leiomyomas. Immunohistochemical analysis showed that both Fas and FasL were localized predominantly in cytosol. Moreover, leiomyomas had an up-regulated Bcl-2 level, which remained high even in the LA-treated cells. Our findings provide molecular evidence to support our previous observations that GnRH-a therapy fails to increase apoptosis in uterine leiomyomas.

This article has been cited by other articles:

				U. A. Kayisli, M. Berkkanoglu, G. Kizilay, L. Senturk, and A. Arici Expression of Proliferative and Preapoptotic Molecules in Human Myometrium and Leiomyoma Throughout the Menstrual Cycle Reproductive Sciences, October 1, 2007; 14(7): 678 - 686. [Abstract] [PDF]

				M. Bilotas, R.I. Baranao, R. Buquet, C. Sueldo, M. Tesone, and G. Meresman Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls Hum. Reprod., March 1, 2007; 22(3): 644 - 653. [Abstract] [Full Text] [PDF]

				C.J. Loy, S. Evelyn, F.K. Lim, M.H. Liu, and E.L. Yong Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-{gamma} ligand, pioglitazone Mol. Hum. Reprod., August 1, 2005; 11(8): 561 - 566. [Abstract] [Full Text] [PDF]

				C. K. Cheng and P. C. K. Leung Molecular Biology of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Their Receptors in Humans Endocr. Rev., April 1, 2005; 26(2): 283 - 306. [Abstract] [Full Text] [PDF]

				F. Parborell, G. Irusta, A. Vitale, O. Gonzalez, A. Pecci, and M. Tesone Gonadotropin-Releasing Hormone Antagonist Antide Inhibits Apoptosis of Preovulatory Follicle Cells in Rat Ovary Biol Reprod, March 1, 2005; 72(3): 659 - 666. [Abstract] [Full Text] [PDF]

				S. Maudsley, L. Davidson, A. J. Pawson, R. Chan, R. L. de Maturana, and R. P. Millar Gonadotropin-Releasing Hormone (GnRH) Antagonists Promote Proapoptotic Signaling in Peripheral Reproductive Tumor Cells by Activating a G{alpha}i-Coupling State of the Type I GnRH Receptor Cancer Res., October 15, 2004; 64(20): 7533 - 7544. [Abstract] [Full Text] [PDF]

				T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF]

				S.-C. Huang, M.-J. Tang, Y.-M. Cheng, K.-F. Hsu, C.-L. Ho, and C.-Y. Chou Enhanced Polyadenosine Diphosphate-Ribosylation in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5009 - 5016. [Abstract] [Full Text] [PDF]